Fidelity International
DNLI icon

Fidelity International’s Denali Therapeutics DNLI Stock Holding History

Fidelity International’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-376,364
Closed -$6.56M – 848
2019
Q4 		$6.56M Hold
376,364
– – 0.01% 544
2019
Q3 		$5.77M Hold
376,364
– – 0.01% 537
2019
Q2 		$7.81M Sell
376,364
-892,672
-70% -$20M 0.01% 494
2019
Q1 		$29.5M Sell
1,269,036
-127,849
-9% -$2.67M 0.05% 316
2018
Q4 		$28.9M Sell
1,396,885
-1,390,094
-50% -$25.2M 0.05% 297
2018
Q3 		$60.6M Sell
2,786,979
-1,749,736
-39% -$28.9M 0.09% 226
2018
Q2 		$69.2M Buy
4,536,715
+351,733
+8% +$6.63M 0.1% 214
2018
Q1 		$82.4M Hold
4,184,982
– – 0.23% 122
2017
Q4 		$65.5M Buy
+4,184,982
New +$75.2M 0.18% 136

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Fidelity International's DNLI Position: Q1 2020 in Review

Fidelity International sold out of Denali Therapeutics (DNLI) in Q1 2020, closing a stake of 376,364 shares — an estimated $6.56M sold.

Fidelity International first reported a position in DNLI in Q4 2017 and held it in 9 quarters. The position peaked at $82.4M in Q1 2018. 128 funds tracked by Wall St. Rank hold DNLI as of Q1 2020.

  • Fidelity International reported no remaining Denali Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Fidelity International sold 376,364 Denali Therapeutics shares in Q1 2020, an estimated $6.56M.
  • Fidelity International first reported a position in Denali Therapeutics in Q4 2017 and held it in 9 quarters.
  • Fidelity International's Denali Therapeutics position peaked at $82.4M in Q1 2018.
  • 128 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2020.

Based on Fidelity International's 13F filing for Q1 2020, filed 14 May 2020.